Reviewing Repligen Corporation (RGEN)’s and Its Peers results

As Biotechnology company, Repligen Corporation (NASDAQ:RGEN) is competing with its peers based on the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Institutional and Insider Ownership

96.6% of Repligen Corporation’s shares are owned by institutional investors. Comparatively, 50.88% of all Biotechnology’s companies shares are owned by institutional investors. On other hand Repligen Corporation has 1.4% of its shares owned by company insiders and an average of 8.18% insiders ownership for its peers.

Profitability

Table 1 has Repligen Corporation and its peers’ net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Repligen Corporation 12.61% 3.90% 3.10%
Industry Average 1,464.25% 88.44% 21.62%

Earnings and Valuation

In next table we are comparing Repligen Corporation and its peers’ valuation, top-line revenue and net income.

Net Income Gross Revenue Price/Earnings Ratio
Repligen Corporation 23.16M 183.70M 205.03
Industry Average 34.08M 2.33M 58.78

Repligen Corporation has higher revenue and P/E Ratio than its peers. With presently higher price-to-earnings ratio Repligen Corporation is more expensive than its peers.

Analyst Recommendations

Table 3 shows breakdown of recent ratings for Repligen Corporation and its peers.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Repligen Corporation 0 1 1 2.50
Industry Average 1.17 1.78 2.01 2.68

$59.5 is the consensus target price of Repligen Corporation, with a potential upside of 1.57%. As a group, Biotechnology companies have a potential upside of 173.20%. The research analysts’ belief based on the data delivered earlier is that Repligen Corporation’s peers are looking more favorable than the stock itself.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Repligen Corporation and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Repligen Corporation -4.25% -8.91% 6.94% 39.49% 79.06% 70.67%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Repligen Corporation has stronger performance than Repligen Corporation’s competitors.

Liquidity

Repligen Corporation has a Current Ratio of 2.1 and a Quick Ratio of 1.7. Competitively, Repligen Corporation’s peers Current Ratio is 7.68 and has 7.52 Quick Ratio. Repligen Corporation’s competitors have better ability to pay short and long-term obligations than Repligen Corporation.

Volatility and Risk

Repligen Corporation has a beta of 0.74 and its 26.00% less volatile than Standard & Poor’s 500. In other hand, Repligen Corporation’s peers have beta of 1.70 which is 70.08% more volatile than Standard & Poor’s 500.

Dividends

Repligen Corporation does not pay a dividend.

Summary

Repligen Corporation beats Repligen Corporation’s competitors on 4 of the 6 factors.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody-based therapeutics, recombinant proteins, and vaccines worldwide. It manufactures various forms of Protein A, a critical component used to purify antibody-based drugs. The company also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields. In addition, it manufactures and sells OPUS pre-packed chromatography columns, which are used in the purification of clinical-stage biologics; and tangential flow filtration cassettes that are used to concentrate clinical and commercial stage biologic drugs. Further, the company has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of FriedreichÂ’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical companies, and contract manufacturers. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.